08 January 2025
QVQ offers unique single-domain antibodies against the class A G protein-coupled receptor CXCR4 (e.g. Q84 and Q85).
In this study, QVQ, together with the group of Professor Martine Smit, further improved the already high affinity and antagonistic potency of one of these sdAbs by constructing various multivalent formats.
Among all generated formats with up to ten VHH domains in one construct, VHH-Fc stood out as particularly effective for improving affinity and potency.
The CXCR4-targeting sdAbs Q84 and Q85 are available as non-modified, cysteine-tagged, and conjugated or genetically fused protein.
